1.    Introduction
1.1.    Report Description
1.1.1.     Objectives of the Study
1.1.2.     Market Scope
1.1.3.     Assumptions
1.2.    Stakeholders

2.    Executive Summary
2.1.    Market Highlights

3.    Research Methodology
3.1.    Overview
3.1.1.     Data Mining
3.2.    Data Sources
3.2.1.     Primary Sources
3.2.2.     Secondary Sources

4.    Europe Pneumococcal Vaccine Market Insights
4.1.    Europe Pneumococcal Vaccine Market – Market Snapshot
4.2.    Europe Pneumococcal Vaccine Market Dynamics
4.2.1.     Drivers and Opportunities
4.2.1.1.    The growing prevalence of pneumonia is driving the market.
4.2.1.2.    The growing R&D for developing novel vaccines propels the market.
4.2.2.     Restraints and Challenges
4.2.2.1.    The high cost of investment in vaccine development is hindering the Europe Pneumococcal Vaccine market growth.
4.3.    Porter’s Five Forces Analysis
4.3.1.     Bargaining Power of Suppliers (Moderate)
4.3.2.     Threats of New Entrants: (Low)
4.3.3.     Bargaining Power of Buyers (Moderate)
4.3.4.     Threat of Substitute (Moderate)
4.3.5.     Rivalry among existing firms (High)
4.4.    PESTEL Analysis
4.5.    Europe Pneumococcal Vaccine Market Trends
4.6.    Value Chain Analysis
4.7.    COVID-19 Impact Analysis

5.    Europe Pneumococcal Vaccine Market, by Type
5.1.    Key Findings
5.2.    Introduction
5.2.1.    Europe Pneumococcal Vaccine Market, by Type, 2023-2032 (USD billion)
5.3.    Pneumococcal Conjugate Vaccine
5.3.1.    Europe Pneumococcal Vaccine Market, by Pneumococcal Conjugate Vaccine, by Region, 2023-2032 (USD billion)
5.4.    Pneumococcal Polysaccharide Vaccine
5.4.1.    Europe Pneumococcal Vaccine Market, by Pneumococcal Polysaccharide Vaccine, by Region, 2023-2032 (USD billion)

6.    Europe Pneumococcal Vaccine Market, by Product
6.1.    Key Findings
6.2.    Introduction
6.2.1.    Europe Pneumococcal Vaccine Market, by Product, 2023-2032 (USD billion)
6.3.    Prevnar 13
6.3.1.    Europe Pneumococcal Vaccine Market, by Prevnar 13, by Region, 2023-2032 (USD billion)
6.4.    Synflorix
6.4.1.    Europe Pneumococcal Vaccine Market, by Synflorix, by Region, 2023-2032 (USD billion)
6.5.    Pneumovax 23
6.5.1.    Europe Pneumococcal Vaccine Market, by Pneumovax 23, by Region, 2023-2032 (USD billion)
6.6.    VAXNEUVANCE
6.6.1.    Europe Pneumococcal Vaccine Market, by VAXNEUVANCE, by Region, 2023-2032 (USD billion)
6.7.    PNEUMOSIL
6.7.1.    Europe Pneumococcal Vaccine Market, by PNEUMOSIL, by Region, 2023-2032 (USD billion)
6.8.    Other
6.8.1.    Europe Pneumococcal Vaccine Market, by Other, by Region, 2023-2032 (USD billion)

7.    Europe Pneumococcal Vaccine Market, by End-user
7.1.     Key Findings
7.2.     Introduction
7.2.1.    Europe Pneumococcal Vaccine Market, by End-user, 2023-2032 (USD billion)
7.3.    Public Sector
7.3.1.    Europe Pneumococcal Vaccine Market, by Public Sector, by Region, 2023-2032 (USD billion)
7.4.    Private Sector
7.4.1.    Europe Pneumococcal Vaccine Market, by Private Sector, by Region, 2023-2032 (USD billion)

8.    Europe Pneumococcal Vaccine Market, by Geography
8.1.    Key Findings
8.2.    Introduction
8.2.1.    Europe Pneumococcal Vaccine Market Assessment, By Geography, 2023-2032 (USD billion)
8.3.    Europe Pneumococcal Vaccine Market – Europe
8.3.1.    Europe Pneumococcal Vaccine Market, by Type, 2023-2032 (USD billion)
8.3.2.    Europe Pneumococcal Vaccine Market, by Product, 2023-2032 (USD billion)
8.3.3.    Europe Pneumococcal Vaccine Market, by End-user, 2023-2032 (USD billion)
8.3.4.    Europe Pneumococcal Vaccine Market – UK
8.3.4.1.    UK: Pneumococcal Vaccine Market, by Type, 2023-2032 (USD billion)
8.3.4.2.    UK: Pneumococcal Vaccine Market, by Product, 2023-2032 (USD billion)
8.3.4.3.    UK: Pneumococcal Vaccine Market, by End-user, 2023-2032 (USD billion)
8.3.5.    Europe Pneumococcal Vaccine Market – France
8.3.5.1.    France: Pneumococcal Vaccine Market, by Type, 2023-2032 (USD billion)
8.3.5.2.    France: Pneumococcal Vaccine Market, by Product, 2023-2032 (USD billion)
8.3.5.3.    France: Pneumococcal Vaccine Market, by End-user, 2023-2032 (USD billion)
8.3.6.    Europe Pneumococcal Vaccine Market – Germany
8.3.6.1.    Germany: Pneumococcal Vaccine Market, by Type, 2023-2032 (USD billion)
8.3.6.2.    Germany: Pneumococcal Vaccine Market, by Product, 2023-2032 (USD billion)
8.3.6.3.    Germany: Pneumococcal Vaccine Market, by End-user, 2023-2032 (USD billion)
8.3.7.    Europe Pneumococcal Vaccine Market – Italy
8.3.7.1.    Italy: Pneumococcal Vaccine Market, by Type, 2023-2032 (USD billion)
8.3.7.2.    Italy: Pneumococcal Vaccine Market, by Product, 2023-2032 (USD billion)
8.3.7.3.    Italy: Pneumococcal Vaccine Market, by End-user, 2023-2032 (USD billion)
8.3.8.    Europe Pneumococcal Vaccine Market – Spain
8.3.8.1.    Spain: Pneumococcal Vaccine Market, by Type, 2023-2032 (USD billion)
8.3.8.2.    Spain: Pneumococcal Vaccine Market, by Product, 2023-2032 (USD billion)
8.3.8.3.    Spain: Pneumococcal Vaccine Market, by End-user, 2023-2032 (USD billion)
8.3.9.    Europe Pneumococcal Vaccine Market – Netherlands
8.3.9.1.    Netherlands: Pneumococcal Vaccine Market, by Type, 2023-2032 (USD billion)
8.3.9.2.    Netherlands: Pneumococcal Vaccine Market, by Product, 2023-2032 (USD billion)
8.3.9.3.    Netherlands: Pneumococcal Vaccine Market, by End-user, 2023-2032 (USD billion)
8.3.10.    Europe Pneumococcal Vaccine Market – Russia
8.3.10.1.    Russia: Pneumococcal Vaccine Market, by Type, 2023-2032 (USD billion)
8.3.10.2.    Russia: Pneumococcal Vaccine Market, by Product, 2023-2032 (USD billion)
8.3.10.3.    Russia: Pneumococcal Vaccine Market, by End-user, 2023-2032 (USD billion)
8.3.11.    Europe Pneumococcal Vaccine Market – Rest of Europe
8.3.11.1.    Rest of Europe: Pneumococcal Vaccine Market, by Type, 2023-2032 (USD billion)
8.3.11.2.    Rest of Europe: Pneumococcal Vaccine Market, by Product, 2023-2032 (USD billion)
8.3.11.3.    Rest of Europe: Pneumococcal Vaccine Market, by End-user, 2023-2032 (USD billion)

9.    Competitive Landscape
9.1.    Expansion and Acquisition Analysis
9.1.1.    Expansion
9.1.2.    Acquisitions
9.2.    Partnerships/Collaborations/Agreements/Exhibitions

10.    Company Profiles
10.1.    Astellas Pharma Inc.
10.1.1.    Company Overview
10.1.2.    Financial Performance
10.1.3.    Type Benchmarking
10.1.4.    Recent Development
10.2.    CSL Ltd
10.2.1.    Company Overview
10.2.2.    Financial Performance
10.2.3.    Type Benchmarking
10.2.4.    Recent Development
10.3.    GSK Plc
10.3.1.    Company Overview
10.3.2.    Financial Performance
10.3.3.    Type Benchmarking
10.3.4.    Recent Development
10.4.    Merck & Co. Inc.
10.4.1.    Company Overview
10.4.2.    Financial Performance
10.4.3.    Type Benchmarking
10.4.4.    Recent Development
10.5.    Panacea Biotech Ltd
10.5.1.    Company Overview
10.5.2.    Financial Performance
10.5.3.    Type Benchmarking
10.5.4.    Recent Development
10.6.    GPN Vaccines
10.6.1.    Company Overview
10.6.2.    Financial Performance
10.6.3.    Type Benchmarking
10.6.4.    Recent Development
10.7.    SK Bioscience
10.7.1.    Company Overview
10.7.2.    Financial Performance
10.7.3.    Type Benchmarking
10.7.4.    Recent Development
10.8.    Bio Pfizer Inc.
10.8.1.    Company Overview
10.8.2.    Financial Performance
10.8.3.    Type Benchmarking
10.8.4.    Recent Development
10.9.    Sanofi S.A
10.9.1.    Company Overview
10.9.2.    Financial Performance
10.9.3.    Type Benchmarking
10.9.4.    Recent Development
10.10.    Serum Life Sciences Ltd
10.10.1.    Company Overview
10.10.2.    Financial Performance
10.10.3.    Type Benchmarking
10.10.4.    Recent Development
10.11.    Talley Group Ltd.
10.11.1.    Company Overview
10.11.2.    Financial Performance
10.11.3.    Type Benchmarking
10.11.4.    Recent Development
10.12.    Walvax Biotechnology Co. Ltd.
10.12.1.    Company Overview
10.12.2.    Financial Performance
10.12.3.    Type Benchmarking
10.12.4.    Recent Development